Effect of rifampin on the pharmacokinetics of BAY73-4506
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
- Healthy male subject - Age: 18 to 45 years (inclusive) at the first screening examination / visit - Body mass index (BMI): 18 to 32 kg/m² (inclusive) - Ability to understand and follow study-related instructions - Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib. An adequate contraception includes the use of condoms or a vasectomy. In addition, adequate birth control measures for the subject’s partner is required, such as a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy.
- Clinically significant disease or condition - Recent serious infection
Austin, United States, 78744
E-mail: [email protected]
Phone: Not Available
A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers
Single Group Assignment